HRP20240170T1 - Organoidi koji sadrže izolirane renalne stanice i njihove uporabe - Google Patents
Organoidi koji sadrže izolirane renalne stanice i njihove uporabe Download PDFInfo
- Publication number
- HRP20240170T1 HRP20240170T1 HRP20240170TT HRP20240170T HRP20240170T1 HR P20240170 T1 HRP20240170 T1 HR P20240170T1 HR P20240170T T HRP20240170T T HR P20240170TT HR P20240170 T HRP20240170 T HR P20240170T HR P20240170 T1 HRP20240170 T1 HR P20240170T1
- Authority
- HR
- Croatia
- Prior art keywords
- cells
- renal
- population
- organoid
- bioactive
- Prior art date
Links
- 210000002220 organoid Anatomy 0.000 title claims 20
- 210000004027 cell Anatomy 0.000 claims 44
- 238000000034 method Methods 0.000 claims 14
- 230000000975 bioactive effect Effects 0.000 claims 13
- 210000002889 endothelial cell Anatomy 0.000 claims 8
- 239000007972 injectable composition Substances 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000007788 liquid Substances 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 238000011862 kidney biopsy Methods 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 4
- 210000005084 renal tissue Anatomy 0.000 claims 4
- 239000012620 biological material Substances 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 238000012606 in vitro cell culture Methods 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 210000003606 umbilical vein Anatomy 0.000 claims 2
- 210000000626 ureter Anatomy 0.000 claims 2
- 208000037157 Azotemia Diseases 0.000 claims 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/25—Urinary tract cells, renal cells
- C12N2502/256—Renal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Materials For Medical Uses (AREA)
Claims (28)
1. Organoid, naznačen time, da sadrži heterogenu populaciju renalnih stanica i ne-renalnu populaciju bioaktivnih stanica,
pri čemu heterogena populacija renalnih stanica potječe iz početne populacije bubrežnih stanica,
pri čemu heterogena populacija renalnih stanica sadrži veći postotak renalnih cjevastih stanica nego početna populacija bubrežnih stanica,
pri čemu početna populacija bubrežnih stanica je uzorak biopsije bubrega, cijelo bubrežno tkivo ili in vitro stanična kultura ustanovljena iz uzorka biopsije bubrega ili iz cijelog bubrežnog tkiva, i
pri čemu heterogena populacija renalnih stanica nadalje sadrži epitelne stanice mokraćovoda,
pri čemu ne-renalna populacija bioaktivnih stanica je ne-renalna populacija endotelnih stanica, ne-renalna populacija endotelnih progenitornih stanica, ne-renalna populacija mezenhimalnih matičnih stanica, ili ne-renalna populacija progenitornih stanica dobivenih iz adipoze, i
pri čemu se organoid kultivira kao klaster od stanica u jednom mediju u suspenziji bez vezivanja na strukturni okvir.
2. Organoid prema patentnom zahtjevu 1, naznačen time, da ne-renalna populacija bioaktivnih stanica jest ne-renalna populacija endotelnih stanica.
3. Organoid prema patentnom zahtjevu 1, naznačen time, da ne-renalna populacija bioaktivnih stanica jest populacija mezenhimalnih matičnih stanica.
4. Organoid prema patentnom zahtjevu 1, naznačen time, da ne-renalna populacija bioaktivnih stanica jest populacija progenitornih stanica dobivenih iz adipoze.
5. Organoid prema patentnom zahtjevu 2, naznačen time, da ne-renalna populacija endotelnih stanica je stanična linija ili sadržava ljudske endotelne stanice pupčane vene.
6. Organoid prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, da su stanice iz heterogene populacije renalnih stanica otporne na hipoksiju.
7. Postupak za tvorbu organoida koji sadrži heterogenu populaciju renalnih stanica i ne-renalnu populaciju bioaktivnih stanica, naznačen time, da navedeni postupak obuhvaća:
suspenzijski uzgoj heterogene populacije renalnih stanica i ne-renalne populacije bioaktivnih stanica u staničnom mediju za uzgoj u 3D kultivacijskom sustavu sve dok se ne formira organoid,
gdje 3D kultivacijski sustav obuhvaća spiner-boce i nedostaje mu egzogeni strukturni okvir na koji se stanice iz heterogene populacije renalnih stanica i ne-renalne populacije bioaktivnih stanica vežu,
gdje se heterogena populacija renalnih stanica izvodi iz početne populacije bubrežnih stanica,
gdje heterogena populacija renalnih stanica sadržava veći postotak renalnih cjevastih stanica nego što ga ima početna populacija bubrežnih stanica,
gdje je početna populacija bubrežnih stanica uzorak biopsije bubrega, cijelo bubrežno tkivo ili in vitro stanična kultura ustanovljena iz uzorka biopsije bubrega ili iz cijelog bubrežnog tkiva, i
gdje heterogena populacija renalnih stanica nadalje sadrži epitelne stanice mokraćovoda, i
gdje ne-renalna populacija bioaktivnih stanica je ne-renalna populacija endotelnih stanica, ne-renalna populacija endotelnih progenitornih stanica, ne-renalna populacija mezenhimalnih matičnih stanica, ili ne-renalna populacija progenitornih stanica dobivenih iz adipoze.
8. Postupak prema patentnom zahtjevu 7, naznačen time, da su stanice iz heterogene populacije renalnih stanica otporne na hipoksiju.
9. Postupak prema patentnom zahtjevu 7, naznačen time, da ne-renalna populacija bioaktivnih stanica jest populacija endotelnih stanica.
10. Postupak prema patentnom zahtjevu 9, naznačen time, da populacija endotelnih stanica je stanična linija ili sadržava ljudske endotelne stanice pupčane vene.
11. Postupak prema patentnom zahtjevu 7, naznačen time, da heterogena populacija renalnih stanica i ne-renalna populacija bioaktivnih stanica su ksenogenične, singenične, alogenične, ili autologne.
12. Postupak prema patentnom zahtjevu 7, naznačen time, da se heterogena populacija renalnih stanica i ne-renalna populacija bioaktivnih stanica kultiviraju odvojeno u prvom vremenskom periodu, te se zatim sastavljaju i kultiviraju u drugom vremenskom periodu.
13. Postupak prema patentnom zahtjevu 12, naznačen time, da drugi vremenski period traje najmanje 24 sata ili traje 24 sata do 72 sata.
14. Postupak prema patentnom zahtjevu 7, naznačen time, da se heterogena populacija renalnih stanica i ne-renalna populacija bioaktivnih stanica nalaze u omjeru 1:1 ili su suspendirane u mediju za rast.
15. Organoid, naznačen time, da je proizveden u skladu s postupkom prema bilo kojem od patentnih zahtjeva 7 do 14.
16. Injektibilna formulacija, naznačena time, da sadrži najmanje jedan organoid prema bilo kojem od patentnih zahtjeva 1 do 5 i tekući medij.
17. Formulacija prema patentnom zahtjevu 16, naznačena time, da se tekući medij bira od medija za stanični rast, Dulbeccove slane otopine s fosfatnim puferom i njihovih kombinacija.
18. Formulacija prema patentnom zahtjevu 16, naznačena time, da se organoid suspendira u tekućem mediju.
19. Injektibilna formulacija, naznačena time, da sadrži najmanje jedan organoid prema bilo kojem od patentnih zahtjeva 1 do 5 i temperaturno osjetljiv biomaterijal za stabiliziranje stanica koji održava
(i) uglavnom kruto stanje na oko 8°C ili niže, i
(ii) uglavnom tekuće stanje na otprilike sobnoj temperaturi ili iznad nje.
20. Formulacija prema patentnom zahtjevu 19, naznačena time, da (i) biomaterijal obuhvaća prijelazno stanje iz krutog u tekuće između oko 8°C i oko sobne temperature ili iznad nje, (ii) uglavnom kruto stanje je stanje u gelu, ili (iii) biomaterijal za stabiliziranje stanica sadrži hidrogel.
21. Formulacija prema patentnom zahtjevu 20, naznačena time, da hidrogel sadrži želatinu.
22. Formulacija prema patentnom zahtjevu 21, naznačena time, da se želatina nalazi u formulaciji na oko 0,5% do oko 1% (masa/volumen) ili se nalazi u formulaciji na oko 0,75% (masa/volumen).
23. Organoid prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je za uporabu u postupku za liječenje bolesti bubrega kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća primjenu najmanje jednog navedenog organoida.
24. Injektibilna formulacija prema bilo kojem od patentnih zahtjeva 19 do 22, naznačena time, da je za uporabu u postupku za liječenje bolesti bubrega kod pojedinca kojemu je to potrebno, pri čemu postupak obuhvaća primjenu navedene injektibilne formulacije.
25. Organoid ili injektibilna formulacija za uporabu prema patentnom zahtjevu 23 ili 24, naznačen/a time, da je pojedinac sisavac.
26. Organoid ili injektibilna formulacija za uporabu prema patentnom zahtjevu 25, naznačen/a time, da je sisavac čovjek.
27. Organoid ili injektibilna formulacija za uporabu prema patentnom zahtjevu 23 ili 24, naznačen/a time, da pojedinac ima bubrežnu bolest.
28. Organoid ili injektibilna formulacija za uporabu prema patentnom zahtjevu 23 ili 24, naznačen/a time, da je poboljšanje vidljivo u bilo kojoj od sljedećih mjera za anemiju (Hct, Hgb, RBC), upalu (WBC), koncentraciju urina (spGrav) i azotemiju (BUN).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361855146P | 2013-05-08 | 2013-05-08 | |
| US201361855152P | 2013-05-09 | 2013-05-09 | |
| PCT/US2014/037275 WO2014182885A2 (en) | 2013-05-08 | 2014-05-08 | Organoids comprising isolated renal cells and uses thereof |
| EP14730323.4A EP2994528B1 (en) | 2013-05-08 | 2014-05-08 | Organoids comprising isolated renal cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240170T1 true HRP20240170T1 (hr) | 2024-04-12 |
Family
ID=50942860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240170TT HRP20240170T1 (hr) | 2013-05-08 | 2014-05-08 | Organoidi koji sadrže izolirane renalne stanice i njihove uporabe |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20160101133A1 (hr) |
| EP (2) | EP4299721A3 (hr) |
| JP (4) | JP6490669B2 (hr) |
| KR (8) | KR102349183B1 (hr) |
| CN (1) | CN105378062A (hr) |
| AU (3) | AU2014262670B2 (hr) |
| CA (1) | CA2911291A1 (hr) |
| DK (1) | DK2994528T3 (hr) |
| ES (1) | ES2970230T3 (hr) |
| FI (1) | FI2994528T3 (hr) |
| HR (1) | HRP20240170T1 (hr) |
| HU (1) | HUE065125T2 (hr) |
| PL (1) | PL2994528T3 (hr) |
| PT (1) | PT2994528T (hr) |
| RU (1) | RU2722361C2 (hr) |
| SI (1) | SI2994528T1 (hr) |
| WO (1) | WO2014182885A2 (hr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| CN117660296A (zh) | 2012-10-24 | 2024-03-08 | 普罗基德尼 | 肾细胞群及其用途 |
| CA2915143C (en) | 2013-06-13 | 2021-08-03 | Orgenesis Ltd. | Cell populations, methods of transdifferentiation and methods of use thereof |
| CN106661548B (zh) | 2014-05-28 | 2020-12-11 | 儿童医院医疗中心 | 用于经由定向分化将前体细胞转化为胃组织的方法和系统 |
| AU2015331848B2 (en) | 2014-10-17 | 2022-03-03 | Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| EP3227116B1 (en) | 2014-12-05 | 2019-07-24 | University of Florida Research Foundation, Inc. | 3d printing using phase changing materials as support |
| MA41296A (fr) | 2014-12-30 | 2017-11-07 | Orgenesis Ltd | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci |
| WO2016130953A1 (en) | 2015-02-13 | 2016-08-18 | University Of Florida Research Foundation, Inc. | High speed 3d printing system for wound and tissue replacement |
| JP6998215B2 (ja) | 2015-05-08 | 2022-02-10 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | ３次元細胞培養のための成長培地 |
| US10815460B2 (en) | 2015-09-03 | 2020-10-27 | The Brigham And Women's Hospital, Inc. | Three-dimensional differentiation of epiblast spheroids to kidney organoids models stage-specific epithelial physiology, morphogenesis, and disease |
| US11027483B2 (en) | 2015-09-03 | 2021-06-08 | University Of Florida Research Foundation, Inc. | Valve incorporating temporary phase change material |
| US20180258382A1 (en) * | 2015-09-18 | 2018-09-13 | University Of Florida Research Foundation, Incorporated | Apparatus for culturing and interacting with a three-dimensional cell culture |
| WO2017096263A1 (en) | 2015-12-04 | 2017-06-08 | University Of Florida Research Foundation, Incorporated | Crosslinkable or functionalizable polymers for 3d printing of soft materials |
| US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| JP7367951B2 (ja) | 2016-05-18 | 2023-10-24 | 慶應義塾 | オルガノイド培養用細胞培養培地 |
| US11124644B2 (en) | 2016-09-01 | 2021-09-21 | University Of Florida Research Foundation, Inc. | Organic microgel system for 3D printing of silicone structures |
| CN110062764B (zh) | 2016-12-05 | 2024-07-02 | 儿童医院医学中心 | 结肠类器官及其制备和使用方法 |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
| WO2018220621A2 (en) * | 2017-05-29 | 2018-12-06 | Orgenesis Ltd. | Vascular secretome, methods of making same, and methods of use thereof |
| US11834680B2 (en) | 2017-06-28 | 2023-12-05 | Rutgers, The State University Of New Jersey | Single kidney cell-derived organoids |
| JP2020536529A (ja) | 2017-10-10 | 2020-12-17 | チルドレンズ ホスピタル メディカル センター | 食道組織および／または臓器組成物およびそれを作製する方法 |
| JP2019196342A (ja) * | 2018-05-10 | 2019-11-14 | 学校法人大阪医科薬科大学 | スタチン封入ナノ粒子製剤、それを含有する歯髄由来幹細胞及びそれを含む細胞製剤。 |
| WO2019222559A1 (en) | 2018-05-16 | 2019-11-21 | University Of Washington | High-throughput automation of organoids for identifying therapeutic strategies |
| KR102094929B1 (ko) * | 2018-07-06 | 2020-03-30 | 한국생명공학연구원 | 신장 스페로이드 및 그의 제조 방법 |
| MX2021001722A (es) * | 2018-08-31 | 2021-07-15 | Timothy A Bertram | Composiciones que comprenden vesiculas derivadas de celulas y usos de las mismas. |
| KR102118807B1 (ko) | 2018-11-26 | 2020-06-03 | 숭실대학교산학협력단 | 3차원 오가노이드 제조용 형상변화형 하이드로젤 몰드 조성물 및 이를 통해 제조된 몰드 |
| KR20200065892A (ko) * | 2018-11-30 | 2020-06-09 | 오가노이드사이언스 주식회사 | 오가노이드의 생체 이식용 조성물 |
| BR112021020451A2 (pt) | 2019-04-11 | 2022-03-08 | Univ Pittsburgh Commonwealth Sys Higher Education | Procedimento para o transplante de célula minimamente invasivo para induzir o desenvolvimento de organogênese in vivo |
| EP4073232A4 (en) * | 2019-12-12 | 2024-01-24 | The Walter and Eliza Hall Institute of Medical Research | ORGANOID CULTURES |
| KR20230007766A (ko) * | 2021-07-06 | 2023-01-13 | 서강대학교산학협력단 | 혈관화된 신장 오가노이드 형성을 위한 세포기질의 최적화 및 오가노이드 칩 개발 |
| CN114507642B (zh) * | 2022-03-17 | 2024-02-02 | 上海纽仁生物医药科技有限公司 | 一种动物神经系统周细胞单细胞的分离方法 |
| CN114732832A (zh) * | 2022-04-08 | 2022-07-12 | 宁夏医科大学总医院 | 一种防宫腔粘连的可植入物 |
| CN116159182B (zh) * | 2023-02-02 | 2024-09-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | 用于治疗脊髓损伤的神经类器官-水凝胶体系及制备方法 |
| WO2025080972A1 (en) * | 2023-10-11 | 2025-04-17 | Regents Of The University Of Minnesota | Organoid-derived exosome products, methods of making, and methods of use |
| WO2025080843A1 (en) * | 2023-10-12 | 2025-04-17 | Prakash Narayan | Selected renal cell population cells, characteristics and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965125A (en) * | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
| US6224893B1 (en) | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
| US6886568B2 (en) * | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
| US7326570B2 (en) * | 2000-06-16 | 2008-02-05 | The Regents Of The University Of California | Induction of tubular morphogenesis using pleiotrophin |
| US7563822B2 (en) | 2002-03-22 | 2009-07-21 | Kissei Pharmaceutical Co., Ltd. | Agents for the prevention or treatment of renal diseases |
| US20040101884A1 (en) * | 2002-03-29 | 2004-05-27 | Lu Dyung Aina M | Molecules for disease detection and treatment |
| CA2637663C (en) * | 2006-01-24 | 2015-06-02 | Brown University | Cell aggregation and encapsulation device and method |
| US7918897B2 (en) | 2006-02-10 | 2011-04-05 | Tengion, Inc. | Scaffolds for organ reconstruction and augmentation |
| AU2007335753B2 (en) * | 2006-12-18 | 2013-12-05 | Ben Gurion University Of The Negev | Scaffolding for tissue regeneration or repair |
| CN103937737B (zh) * | 2008-11-12 | 2023-05-23 | 因瑞金公司 | 分离的肾细胞及其用途 |
| GB201111244D0 (en) * | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
| PL3190177T3 (pl) * | 2010-05-12 | 2022-06-06 | Prokidney | Bioaktywne komórki nerkowe |
| WO2011156642A1 (en) * | 2010-06-11 | 2011-12-15 | Tengion, Inc. | Erythropoietin-expressing adipose cell populations |
| US9724367B2 (en) * | 2010-11-10 | 2017-08-08 | Regenmed (Cayman) Ltd. | Injectable formulations for organ augmentation |
| CA2837462C (en) | 2011-05-27 | 2021-06-01 | DePuy Synthes Products, LLC | Bioartificial proximal tubule systems and methods of use |
| CN102366713A (zh) * | 2011-09-02 | 2012-03-07 | 华中科技大学 | 一种具有生理功能的透析膜材料及其制备方法 |
| WO2013063588A1 (en) * | 2011-10-28 | 2013-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Ex vivo culture, proliferation and expansion of primary tissue organoids |
-
2014
- 2014-05-08 CA CA2911291A patent/CA2911291A1/en active Pending
- 2014-05-08 KR KR1020217023058A patent/KR102349183B1/ko active Active
- 2014-05-08 PT PT147303234T patent/PT2994528T/pt unknown
- 2014-05-08 AU AU2014262670A patent/AU2014262670B2/en active Active
- 2014-05-08 KR KR1020227000187A patent/KR102556951B1/ko active Active
- 2014-05-08 US US14/889,820 patent/US20160101133A1/en not_active Abandoned
- 2014-05-08 KR KR1020247016715A patent/KR102710014B1/ko active Active
- 2014-05-08 KR KR1020237044395A patent/KR102668827B1/ko active Active
- 2014-05-08 EP EP23208039.0A patent/EP4299721A3/en active Pending
- 2014-05-08 FI FIEP14730323.4T patent/FI2994528T3/fi active
- 2014-05-08 DK DK14730323.4T patent/DK2994528T3/da active
- 2014-05-08 EP EP14730323.4A patent/EP2994528B1/en active Active
- 2014-05-08 KR KR1020217006496A patent/KR102281921B1/ko active Active
- 2014-05-08 WO PCT/US2014/037275 patent/WO2014182885A2/en active Application Filing
- 2014-05-08 RU RU2015152257A patent/RU2722361C2/ru active
- 2014-05-08 KR KR1020247031477A patent/KR102757386B1/ko active Active
- 2014-05-08 KR KR1020157031883A patent/KR102225312B1/ko active Active
- 2014-05-08 HR HRP20240170TT patent/HRP20240170T1/hr unknown
- 2014-05-08 PL PL14730323.4T patent/PL2994528T3/pl unknown
- 2014-05-08 JP JP2016513062A patent/JP6490669B2/ja active Active
- 2014-05-08 HU HUE14730323A patent/HUE065125T2/hu unknown
- 2014-05-08 SI SI201432063T patent/SI2994528T1/sl unknown
- 2014-05-08 ES ES14730323T patent/ES2970230T3/es active Active
- 2014-05-08 CN CN201480025693.8A patent/CN105378062A/zh active Pending
- 2014-05-08 KR KR1020237023969A patent/KR102618557B1/ko active Active
-
2019
- 2019-02-27 JP JP2019034989A patent/JP7062605B2/ja active Active
-
2020
- 2020-06-11 AU AU2020203860A patent/AU2020203860B2/en active Active
-
2022
- 2022-02-18 US US17/675,223 patent/US20220249569A1/en active Pending
- 2022-03-01 JP JP2022030862A patent/JP7493252B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206151A patent/AU2023206151A1/en active Pending
-
2024
- 2024-05-14 JP JP2024078330A patent/JP2024105523A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240170T1 (hr) | Organoidi koji sadrže izolirane renalne stanice i njihove uporabe | |
| JP2016519930A5 (hr) | ||
| Galipeau | The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? | |
| Hu et al. | Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice | |
| US9315776B2 (en) | Wharton's jelly mesenchymal stem cells and uses thereof | |
| Wahl et al. | In vitro evaluation of scaffolds for the delivery of mesenchymal stem cells to wounds | |
| Liu et al. | Metabolic regulation of mesenchymal stem cell in expansion and therapeutic application | |
| Popa et al. | Cryopreservation of cell laden natural origin hydrogels for cartilage regeneration strategies | |
| Gao et al. | Adipose-derived mesenchymal stem cells promote liver regeneration and suppress rejection in small-for-size liver allograft | |
| Ozturk et al. | Experimental stem cell therapies on burn wound: do source, dose, timing and method matter? | |
| Chabot et al. | Transient warming events occurring after freezing impairs umbilical cord–derived mesenchymal stromal cells functionality | |
| Miceli et al. | Comparative study of the production of soluble factors in human placenta-derived mesenchymal stromal/stem cells grown in adherent conditions or as aggregates in a catheter-like device | |
| Chinnici et al. | Mesenchymal stromal cells isolated from human fetal liver release soluble factors with a potential role in liver tissue repair | |
| Wittig et al. | Viability and functionality of mesenchymal stromal cells loaded on collagen microspheres and incorporated into plasma clots for orthopaedic application: effect of storage conditions | |
| ES2580377T3 (es) | Método para cultivar células en un medio que contiene lisado de plaquetas | |
| Petrenko et al. | Comparison of the methods for seeding human bone marrow mesenchymal stem cells to macroporous alginate cryogel carriers | |
| Chouw et al. | Factors influencing the therapeutic potential of the MSC-derived secretome | |
| US11395863B2 (en) | Modification method for sheet-shaped cell culture | |
| Sanap et al. | Ascorbic acid and IFNγ preconditioning enhance the potency of human mesenchymal stem cells to ameliorate LPS induced cytokine storm | |
| Robert et al. | Glycoprotein Ibα receptor instability is associated with loss of quality in platelets produced in culture | |
| KR20160006127A (ko) | 줄기세포의 보관 안정성 증진용 조성물 | |
| Zhang et al. | Bone marrow mesenchymal stem cells suppress activated CD4+ T cells proliferation through TGF-beta and IL10 dependent of autophagy in pathological hypoxic microenvironment | |
| Bn et al. | Exploring the therapeutic potential of allogeneic amniotic membrane for quality wound healing in rabbit model | |
| KR20140042687A (ko) | 트레할로스 함유 세포 세정용액을 이용한 접착세포의 세정 방법 | |
| Pieper et al. | Isolation of mesenchymal stromal cells from peripheral blood of ST elevation myocardial infarction patients |